Systemic Aspergillosis and Systemic Candidiasis Market Global Report 2027

    Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type (Voriconazole, Liposomal, Amphotericin B, Systemic Oral Azoles, Topical, Antifungal Agents, Others); Application (Chronic, Pulmonary Aspergillosis (CPA), Allergic, Bronchopulmonary Aspergillosis (ABPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Others), and Geography

    Publication Month: Jan 2021 | Report Code: TIPRE00016906 | No. of Pages: 160 | Category: Pharmaceuticals | Status: Published

    The systemic aspergillos is and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019. The market is estimated to grow at a CAGR of 4.0% from 2020 to 2027.

    Candida Auris is a fungus that causes a serious global health threat. It causes severe illness in hospitalized patients in several countries, including the US. Patients can remain colonized with C. Auris for a long time. Also, C. Auris can persist on surfaces in healthcare environments. This can result in the spread of C. Auris between patients in healthcare facilities. According to a CDC report of 2021, US cases of C. Auris have been found in patients who had recent stays in healthcare facilities in Egypt, India, Kenya, Kuwait, Pakistan, South Africa, South Korea, the UAE, and Venezuela, which also have documented cases. Thus, this can be a hospital-acquired infection. The emergence of Candida Auris is considered as one of the most serious problems associated with nosocomial transmission and infection control practices in the hospital environment. Additionally, the CDC stated that 560 cases of C. Auris infections were reported in the US as of January 31, 2019. Furthermore, despite execution of countermeasures to limit fungal infections in intensive care units (ICUs), cases continue to be observed and reported, with a tendency toward an endemic pattern. This shows the ability of C. Auris to persistent infection in the clinical environment, enabling its transmission within the critical care setting. Unlike other Candida species, C. Auris can colonize different anatomical sites (e.g., skin, axilla, rectum, and stool) and contaminate the hospital equipment and surfaces, creating a vicious cycle of spreading, acquisition, and infection, particularly in ICUs.

    Additionally, according to an NCBI report published in Jan 2020, increasing number of travels to foreign countries and exposure to healthcare in countries with extensive C. Auris transmission as well as the higher flow of migrants, are factors that can contribute to the quick dissemination of this species. Further, a higher frequency of C. Auris was found in public hospitals as compared to the private ones, which may be connected to overcrowding and compromised infection control measures. Moreover, 7 out of every 1,000 patients admitted in ICUs across India are affected with a fungal infection, says preliminary analysis of data collected by researchers in Post Graduate Institute of Medical Education and Research, Chandigarh. The data was collected from 27 hospital ICUs across the country (11 government hospitals and 16 private hospitals). Thus, increasing incidence of hospital-acquired fungal infection is creating the demand for drugs that can prevent systemic aspergillosis and systemic candidiasis. This, in turn, is likely to boost the growth of the Systemic Aspergillosis and Systemic Candidiasis market


    Lucrative Regional Markets for Systemic Aspergillosis and Systemic Candidiasis
    Lucrative Regional Markets for Systemic Aspergillosis and Systemic Candidiasis

    Get more information on this report :



    Market Insights


    Rise in Prevalence of Fungal Diseases

    Systemic aspergillosis and systemic candidiasis are types of fungal infections. Aspergillosis infection is caused by molds. It majorly affects the respiratory tract of an individual. It is a severe pulmonary infection caused by Aspergillus—a common fungus that affects people with weakened immune systems or lung diseases. Moreover, severe fungal infections occur due to other health problems, including asthma, cancer, AIDS, organ transplantation, and corticosteroid therapies. Early diagnosis allows prompt antifungal treatment; however, this is often delayed or unavailable, leading to severe chronic illness, death, or blindness. For instance, according to the Journal of Fungi published in March 2017, HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma, and increasing incidence of cancers are the primary drivers of fungal infections in both developed and developing countries globally. Furthermore, a report published by the National Library of Medicine National Institutes of Health in October 2017 stated that ~3,000,000 cases of chronic pulmonary aspergillosis; ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS; ~700,000 cases of invasive candidiasis; ~500,000 cases of Pneumocystis jirovecii pneumonia; ~250,000 cases of invasive aspergillosis; ~100,000 cases of disseminated histoplasmosis; over 10,000,000 cases of fungal asthma; and ~1,000,000 cases of fungal keratitis occur annually across the world. Moreover, according to a report by the Centers for Disease Control and Prevention (CDC), ~1,595 cases of Candida Auris have been observed in different states of the US.

    Type Insights

    Based on type, the systemic aspergillosis and systemic candidiasis market is segmented into voriconazole, liposomal amphotericin b, systemic oral azoles, topical antifungal agents, and others. In 2019, the systemic oral azoles segment held the largest share of the market. The same segment is expected to grow at the fastest rate during the forecast period owing to rising number of invasive fungal infections.

    Global Systemic Aspergillosis and Systemic Candidiasis Market, by Product – 2019 and 2027
    Global Systemic Aspergillosis and Systemic Candidiasis Market, by Product – 2019 and 2027

    Get more information on this report :



    Application Insights

    Based on application, the global systemic aspergillosis and systemic candidiasis market is segmented into chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), gastrointestinal candidiasis, genitourinary tract, candidiasis, and others. In 2019, the allergic bronchopulmonary aspergillosis (ABPA) segment held the largest share of the market. The same segment is expected to grow at the fastest rate during the forecast period.

    Strategic Insights

    Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios to meet the growing consumer demand. The systemic aspergillosis and systemic candidiasis market players are adopting the collaborations strategy to enlarge customer base worldwide, which also permits them to maintain their brand name globally.

    Systemic Aspergillosis and Systemic Candidiasis Market – by Type

    • Systemic Oral Azoles
    • Voriconazole
    • Liposomal Amphotericin B
    • Topical Antifungal Agents
    • Others

    Systemic Aspergillosis and Systemic Candidiasis Market – by Application

    • Allergic Bronchopulmonary Aspergillosis (ABPA)
    • Chronic Pulmonary Aspergillosis (CPA)
    • Gastrointestinal Candidiasis
    • Genitourinary Tract Candidiasis
    • Others

    Systemic Aspergillosis and Systemic Candidiasis Market – by Geography

    • North America

      • US
      • Canada
      • Mexico
    • Europe

      • France
      • Germany
      • Italy
      • UK
      • Spain
      • Rest of Europe
    • Asia Pacific (APAC)

      • China
      • India
      • South Korea
      • Japan
      • Australia
      • Rest of Asia Pacific
    • Middle East & Africa (MEA)

      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of Middle East & Africa
    • South and Central America

      • Brazil
      • Argentina
      • Rest of South America

    Company Profiles

    • Novartis Ag
    • Sanofi-Aventis
    • Pfizer, Inc.
    • Merck And Co., Inc.
    • Enzon Pharmaceuticals Inc.
    • Bayer Ag
    • Astellas Pharma, Inc.
    • Glaxosmithkline Plc
    • Abbott
    • Cipla

    1. Introduction

    1.1 Scope of the Study

    1.2 The Insight Partners Research Report Guidance

    1.3 Market Segmentation

    1.3.1 Global Systemic Aspergillosis and Systemic Candidasis Market – By Type

    1.3.2 Global Systemic Aspergillosis and Systemic Candidasis Market – By Application

    1.3.3 Global Systemic Aspergillosis and Systemic Candidasis Market – By Geography

    2. Systemic Aspergillosis And Systemic Candidasis Market – Key Takeaways

    3. Research Methodology

    3.1 Coverage

    3.2 Secondary Research

    3.3 Primary Research

    4. Global Systemic Aspergillosis and Systemic Candidasis Market– Market Landscape

    4.1 Overview

    4.2 PEST Analysis

    4.2.1 North America – PEST Analysis

    4.2.2 Europe – PEST Analysis

    4.2.3 Asia Pacific – PEST Analysis

    4.2.4 Middle East and Africa (MEA) – PEST Analysis

    4.2.5 South and Central America (SCAM) – PEST Analysis

    4.3 Expert Opinions

    4.4 Clinical Trials Phases of Products Offered by Companies

    4.5 Candida Specific Products

    5. Systemic Aspergillosis and Systemic Candidasis Market – Key Market Dynamics

    5.1 Market Drivers

    5.1.1 Rise in Prevalence of Fungal Diseases

    5.1.2 Rising Hospital Acquired Fungal Infection

    5.2 Market Restraints

    5.2.1 Increasing Resistance to Antifungal Drugs

    5.2.2 Side Effects of Antifungal Drugs

    5.3 Market Opportunities

    5.3.1 Increase in R&D Activities and Pipeline of New Drug

    5.4 Future Trends

    5.4.1 Consolidation of Market

    5.5 Impact Analysis

    6. Systemic Aspergillosis And Systemic Candidasis Market – Global Analysis

    6.1 Global Systemic Aspergillosis And Systemic Candidasis Market Revenue Forecast And Analysis

    6.2 Global Systemic Aspergillosis And Systemic Candidasis Market, By Geography - Forecast And Analysis

    6.3 Market Positioning

    7. Systemic Aspergillosis and Systemic Candidasis Market Analysis– by Type

    7.1 Overview

    7.2 Global Systemic Aspergillosis and Systemic Candidasis Market, by Type, 2019 and 2027 (%)

    7.3 Voriconazole

    7.3.1 Overview

    7.3.2 Global Voriconazole Market Revenue and Forecasts to 2027 (US$ Mn)

    7.4 Liposomal Amphotericin B

    7.4.1 Overview

    7.4.2 Global Liposomal Amphotericin B Market Revenue and Forecasts to 2027 (US$ Mn)

    7.5 Systemic Oral Azoles

    7.5.1 Overview

    7.5.2 Global Systemic Oral Azoles Market Revenue and Forecasts to 2027 (US$ Mn)

    7.6 Topical Antifungal Agents

    7.6.1 Overview

    7.6.2 Global Topical Antifungal Agents Market Revenue and Forecasts to 2027 (US$ Mn)

    7.7 Others

    7.7.1 Overview

    7.7.2 Global Others Market Revenue and Forecasts to 2027 (US$ Mn)

    8. Systemic Aspergillosis and Systemic Candidasis Market Analysis– by Application

    8.1 Overview

    8.2 Global Systemic Aspergillosis and Systemic Candidasis Market, by Type, 2019 and 2027 (%)

    8.3 Chronic Pulmonary Aspergillosis (CPA)

    8.3.1 Overview

    8.3.2 Global Chronic pulmonary aspergillosis (CPA) Market Revenue and Forecasts to 2027 (US$ Mn)

    8.4 Allergic Bronchopulmonary Aspergillosis (ABPA)

    8.4.1 Overview

    8.4.2 Global Allergic bronchopulmonary aspergillosis (ABPA) Market Revenue and Forecasts to 2027 (US$ Mn)

    8.5 Gastrointestinal Candidiasis

    8.5.1 Overview

    8.5.2 Global Gastrointestinal Candidiasis Market Revenue and Forecasts to 2027 (US$ Mn)

    8.6 Genitourinary Tract Candidiasis

    8.6.1 Overview

    8.6.2 Global Genitourinary Tract Candidiasis Market Revenue and Forecasts to 2027 (US$ Mn)

    8.7 Others

    8.7.1 Overview

    8.7.2 Global Others Market Revenue and Forecasts to 2027 (US$ Mn)

    9. Systemic Aspergillosis and Systemic Candidiasis Market – Geographic Analysis

    9.1 North America: Systemic Aspergillosis and Systemic Candidiasis Market

    9.1.1 Overview

    9.1.2 North America: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.1.3 North America: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.1.4 North America: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.1.5 North America: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    9.1.6 US: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.1.6.1 US: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.1.6.2 US: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.1.6.3 US: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.1.7 Canada: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.1.7.1 Canada: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.1.7.2 Canada: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.1.7.3 Canada: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.1.8 Mexico: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.1.8.1 Mexico: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.1.8.2 Mexico: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.1.8.3 Mexico: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.2 Europe: Systemic Aspergillosis and Systemic Candidiasis Market

    9.2.1 Overview

    9.2.2 Europe: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.3 Europe: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.2.4 Europe: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.2.5 Europe: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    9.2.6 Germany: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.6.1 Germany: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.6.2 Germany: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.2.6.3 Germany: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.2.7 UK: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.7.1 UK: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.7.2 UK: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.2.7.3 UK: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.2.8 France: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.8.1 France: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.8.2 France: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.2.8.3 France: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.2.9 Italy: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.9.1 Italy: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.9.2 Italy: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.2.9.3 Italy: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.2.10 Spain: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.10.1 Spain: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.10.2 Spain: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.2.10.3 Spain: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.2.11 Rest of Europe: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.11.1 Rest of Europe: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.2.11.2 Rest of Europe: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.2.11.3 Rest of Europe: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.3 Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market

    9.3.1 Overview

    9.3.2 Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.3 Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.3.4 Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.3.5 Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    9.3.6 China: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.6.1 China: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.6.2 China: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.3.6.3 China: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.3.7 Japan: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.7.1 Japan: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.7.2 Japan: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.3.7.3 Japan: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.3.8 India: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.8.1 India: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.8.2 India: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.3.8.3 India: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.3.9 Australia: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.9.1 Australia: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.9.2 Australia: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.3.9.3 Australia: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.3.10 South Korea: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.10.1 South Korea: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.10.2 South Korea: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.3.10.3 South Korea: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.3.11 Rest of Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.11.1 Rest of Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.3.11.2 Rest of Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.3.11.3 Rest of Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.4 Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market

    9.4.1 Overview

    9.4.2 Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.4.3 Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.4.4 Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.4.5 Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    9.4.6 South Africa: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.4.6.1 South Africa: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.4.6.2 South Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.4.6.3 South Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.4.7 Saudi Arabia: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.4.7.1 Saudi Arabia: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.4.7.2 Saudi Arabia: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.4.7.3 Saudi Arabia: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.4.8 UAE: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.4.8.1 UAE: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.4.8.2 UAE: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.4.8.3 UAE: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.4.9 Rest of Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.4.9.1 Rest of Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.4.9.2 Rest of Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.4.9.3 Rest of Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.5 South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market

    9.5.1 Overview

    9.5.2 South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.5.3 South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.5.4 South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.5.5 South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    9.5.6 Brazil: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.5.6.1 Brazil: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.5.6.2 Brazil: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.5.6.3 Brazil: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.5.7 Argentina: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.5.7.1 Argentina: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.5.7.2 Argentina: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.5.7.3 Argentina: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    9.5.8 Rest of South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.5.8.1 Rest of South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    9.5.8.2 Rest of South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

    9.5.8.3 Rest of South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

    10. Impact of COVID-19 Pandemic on Global Systemic Aspergillosis and Systemic Candidiasis Market

    10.1 North America: Impact Assessment of COVID-19 Pandemic

    10.2 Europe: Impact Assessment Of COVID-19 Pandemic

    10.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic

    10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic

    10.5 South and Central America: Impact Assessment of COVID-19 Pandemic

    11. Systemic Aspergillosis and Systemic Candidiasis Market–Industry Landscape

    11.1 Overview

    11.2 Recent Growth Strategies In The Systemic Aspergillosis And Systemic Candidiasis Market

    12. COMPANY PROFILES

    12.1 Novartis AG

    12.1.1 Key Facts

    12.1.2 Business Description

    12.1.3 Products and Services

    12.1.4 Financial Overview

    12.1.5 SWOT Analysis

    12.1.6 Key Developments

    12.2 Sanofi

    12.2.1 Key Facts

    12.2.2 Business Description

    12.2.3 Products and Services

    12.2.4 Financial Overview

    12.2.5 SWOT Analysis

    12.2.6 Key Developments

    12.3 Pfizer Inc.

    12.3.1 Key Facts

    12.3.2 Business Description

    12.3.3 Products and Services

    12.3.4 Financial Overview

    12.3.5 SWOT Analysis

    12.3.6 Key Developments

    12.4 Merck & Co., Inc.

    12.4.1 Key Facts

    12.4.2 Business Description

    12.4.3 Products and Services

    12.4.4 Financial Overview

    12.4.5 SWOT Analysis

    12.4.6 Key Developments

    12.5 Bayer AG

    12.5.1 Key Facts

    12.5.2 Business Description

    12.5.3 Products and Services

    12.5.4 Financial Overview

    12.5.5 SWOT Analysis

    12.5.6 Key Developments

    12.6 Astellas Pharma Inc.

    12.6.1 Key Facts

    12.6.2 Business Description

    12.6.3 Products and Services

    12.6.4 Financial Overview

    12.6.5 SWOT Analysis

    12.6.6 Key Developments

    12.7 GlaxoSmithKline plc.

    12.7.1 Key Facts

    12.7.2 Business Description

    12.7.3 Products and Services

    12.7.4 Financial Overview

    12.7.5 SWOT Analysis

    12.7.6 Key Developments

    12.8 Abbott

    12.8.1 Key Facts

    12.8.2 Business Description

    12.8.3 Products and Services

    12.8.4 Financial Overview

    12.8.5 SWOT Analysis

    12.8.6 Key Developments

    12.9 Cipla Inc.

    12.9.1 Key Facts

    12.9.2 Business Description

    12.9.3 Products and Services

    12.9.4 Financial Overview

    12.9.5 SWOT Analysis

    12.9.6 Key Developments

    12.10 ENZON PHARMACEUTICALS, INC

    12.10.1 Key Facts

    12.10.2 Business Description

    12.10.3 Products and Services

    12.10.4 Financial Overview

    12.10.5 SWOT Analysis

    12.10.6 Key Developments

    13. Appendix

    13.1 About the Insight Partners

    13.2 Glossary of Terms

    LIST OF TABLES

    Table 1. Clinical Trials Phases of Products Offered by Companies

    Table 2. Candida Specific Products

    Table 3. Clinical cases of Candida auris reported by U.S. states, as of November 30, 2020

    Table 4. North America Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 5. North America Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 6. US: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 7. US: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027

    Table 8. Canada: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 9. Canada: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 10. Mexico: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 11. Mexico: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 12. Europe Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 13. Europe Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 14. US: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 15. Germany: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027

    Table 16. UK: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 17. UK: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 18. France: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 19. France: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 20. Italy: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 21. Italy: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 22. Spain: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 23. Spain: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 24. Rest of Europe: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 25. Rest of Europe: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 26. Asia PacificSystemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 27. Asia PacificSystemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 28. US: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 29. China: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027

    Table 30. Japan: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 31. Japan: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 32. India: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 33. India: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 34. Australia: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 35. Australia: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 36. South Korea: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 37. South Korea: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 38. Rest of Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 39. Rest of Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 40. Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 41. Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 42. US: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 43. South Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027

    Table 44. Saudi Arabia: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 45. Saudi Arabia: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 46. UAE: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 47. UAE: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 48. Rest of Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 49. Rest of Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 50. South and Central America Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 51. South and Central America Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 52. US: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 53. Brazil: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027

    Table 54. Argentina: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 55. Argentina: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 56. Rest of South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

    Table 57. Rest of South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

    Table 58. Glossary of Terms, Systemic Aspergillosis And Systemic Candidiasis Market

    LIST OF FIGURES

    Figure 1. Systemic Aspergillosis And Systemic Candidasis Market Segmentation

    Figure 2. Systemic Aspergillosis And Systemic Candidasis Market, By Region

    Figure 3. Global Systemic Aspergillosis And Systemic Candidasis Market Overview

    Figure 4. Systemic Oral Azoles Segment Held Largest Share of Type Segment In Systemic Aspergillosis And Systemic Candidasis Market

    Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period

    Figure 6. Global Systemic Aspergillosis And Systemic Candidasis Market, By Geography (USD Million)

    Figure 7. Global Systemic Aspergillosis And Systemic Candidasis Market- Leading Country Markets (USD Million)

    Figure 8. Global Systemic Aspergillosis And Systemic Candidasis Market, Industry Landscape

    Figure 9. North America PEST Analysis

    Figure 10. Europe PEST Analysis

    Figure 11. Asia Pacific PEST Analysis

    Figure 12. Middle East and Africa (MEA) PEST Analysis

    Figure 13. South and Central America (SCAM) PEST Analysis

    Figure 14. Systemic Aspergillosis and Systemic Candidasis Market Impact Analysis of Drivers and Restraint

    Figure 15. Global Systemic aspergillosis and systemic candidasis Market – Revenue Forecast And Analysis – 2019- 2027

    Figure 16. Global Systemic Aspergillosis And Systemic Candidasis Market – By Geography Forecast and Analysis – 2019- 2027

    Figure 17. Global Systemic Aspergillosis And Systemic Candidasis Market – By Geography Forecast and Analysis – 2019 - 2027

    Figure 18. Global Systemic Aspergillosis and Systemic Candidasis Market breakdown, by Type, 2019 and 2027 (%)

    Figure 19. Global Voriconazole Market Revenue And Forecasts to 2027 (US$ Mn)

    Figure 20. Global Liposomal Amphotericin B Market Revenue and Forecasts to 2027 (US$ Mn)

    Figure 21. Global Systemic Oral Azoles Market Revenue and Forecasts to 2027 (US$ Mn)

    Figure 22. Global Topical Antifungal Agents Market Revenue and Forecasts to 2027 (US$ Mn)

    Figure 23. Global others Market Revenue and Forecasts to 2027 (US$ Mn)

    Figure 24. Global Systemic Aspergillosis and Systemic Candidasis Market breakdown, by Type, 2019 and 2027 (%)

    Figure 25. Global Chronic pulmonary aspergillosis (CPA) Market Revenue And Forecasts to 2027 (US$ Mn)

    Figure 26. Global Allergic bronchopulmonary aspergillosis (ABPA)Market Revenue and Forecasts to 2027 (US$ Mn)

    Figure 27. Global Gastrointestinal Candidiasis Market Revenue and Forecasts to 2027 (US$ Mn)

    Figure 28. Global Genitourinary Tract Candidiasis Market Revenue and Forecasts to 2027 (US$ Mn)

    Figure 29. Global others Market Revenue and Forecasts to 2027 (US$ Mn)

    Figure 30. North America: Systemic Aspergillosis and Systemic Candidiasis Market, by Key Country – Revenue (2019) (USD Million)

    Figure 31. North America: Systemic Aspergillosis and Systemic Candidiasis Market Revenue and Forecast to 2027 (USD Million)

    Figure 32. North America: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    Figure 33. US: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 34. Canada: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 35. Mexico: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 36. Europe: Systemic Aspergillosis and Systemic Candidiasis Market, by Key Country – Revenue (2019) (USD Million)

    Figure 37. Europe: Systemic Aspergillosis and Systemic Candidiasis Market Revenue and Forecast to 2027 (USD Million)

    Figure 38. Europe: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    Figure 39. Germany: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 40. UK: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 41. France: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 42. Italy: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 43. Spain: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 44. Rest of Europe: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 45. Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market, by Key Country – Revenue (2019) (USD Million)

    Figure 46. Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market Revenue and Forecast to 2027 (USD Million)

    Figure 47. Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    Figure 48. China: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 49. Japan: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 50. India: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 51. Australia: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 52. South Korea: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 53. Rest of Asia Pacific: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 54. Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Key Country – Revenue (2019) (USD Million)

    Figure 55. Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market Revenue and Forecast to 2027 (USD Million)

    Figure 56. Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    Figure 57. South Africa: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 58. Saudi Arabia: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 59. UAE: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 60. Rest of Middle East & Africa: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 61. South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market, by Key Country – Revenue (2019) (USD Million)

    Figure 62. South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market Revenue and Forecast to 2027 (USD Million)

    Figure 63. South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

    Figure 64. Brazil: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 65. Argentina: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 66. Rest of South and Central America: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

    Figure 67. Impact of COVID-19 Pandemic in North American Country Markets

    Figure 68. Impact of COVID-19 Pandemic on Systemic Aspergillosis And Systemic Candidiasis Market in Asia Pacific Countries

    Figure 69. Impact Of COVID-19 Pandemic in Middle East and Africa Market

    Figure 70. Impact Of COVID-19 Pandemic in South and Central America Market

    The List of Companies - Systemic Aspergillosis and Systemic Candidiasis Market

    1. Novartis Ag
    2. Sanofi-Aventis
    3.  Pfizer, Inc
    4.  Merck And Co. Inc
    5.  Enzon Pharmaceuticals, Inc
    6.  Bayer Ag
    7. Astellas Pharma Inc
    8.  Glaxosmithkline Plc
    9.  Abbott
    10.  Cipla
    • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Systemic Aspergillosis and Systemic Candidasis Market.
    • Highlights key business priorities in order to assist companies to realign their business strategies.
    • The key findings and recommendations highlight crucial progressive industry trends in the global percutaneous mechanical circulatory support devices  market, thereby allowing players across the value chain to develop effective long-term strategies.
    • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
    • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
    • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
    TIPRE00016906
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market



    Frequently Asked Questions

    The systemic aspergillosis and systemic candidiasis are the type of fungal infections. The aspergillosis infection is caused by molds and majorly affect the respiratory tract of an individual. The aspergillosis is not a severe condition but people with weakened immune system are prone to it. The candidiasis is caused by fungus called candida. The candidiasis is also known as thrush. The symptoms of candidiasis include patches in mouth and tongue. The treatment options for aspergillosis and candidiasis include drug therapy and surgery in some cases.
    Driving factors for the market include rise in prevalence of fungal diseases and rising hospital acquired fungal infection. however, increasing resistance to antifungal drugs and side effects of antifungal drugs is likely to hamper the growth of the market during the forecast period.
    Allergic bronchopulmonary aspergillosis (ABPA) have fastest growing segment among all segments.

    Pricing
    • $3000
    • $4550
    • $6550
    • $8550

        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount   Speak to Analyst